Recursion Pharmaceuticals, Inc.

RXRX

$2.03B

Mid Cap

NASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaSALT LAKE CITY800 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Next month

Market Overview

Stock performance and key metrics

RXRX News

Catalyst Timeline

4 upcoming, 0 past

No catalysts found.

4 more catalysts beyond 14 days

Start a 48-hour free trial to see all upcoming catalysts

Pro

Drug Pipeline

GTAEXS617

Phase 2

Advanced Solid Tumor

REC-4881

Phase 2

AXIN1 Gene Mutation

REC-994

Phase 2

Cerebral Cavernous Malformation

REC-1245

Phase 2

Unresectable

Drug Name	Phase	Indication	Designations	Patent
GTAEXS617	Phase 2	Advanced Solid Tumor	-	-
REC-4881	Phase 2	AXIN1 Gene Mutation	-	-
REC-994	Phase 2	Cerebral Cavernous Malformation	-	-
REC-1245	Phase 2	Unresectable	-	-

Catalyst Verdict

Market-Implied Move

Regulatory Approvals

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Recursion Pharmaceuticals, Inc.

Market Overview

RXRX News

Catalyst Timeline

Pipeline & FDA Submissions

AI Predictions & Institutional Flow

Market Intelligence

Regulatory Approvals